 Shares of Epizyme Inc. were down 2.3 in premarket trading on Friday, the day after it said the Food and Drug Administration had approved Tazverik as a treatment for relapsed or refractory follicular lymphoma. Tazverik was first approved by the FDA in January, to treat epithelioid sarcoma. In our view, there remains no clear standard of care in the relapsed andor refractory FL population as not all patients benefit from todays available therapies, Dr. Shefali Agarwal, Epizymes chief medical officer of Epizyme, said in a news release. However, the labels for the two new indications are narrower than some analysts had expected. We believe this label may disappoint some investors who had expected a broad, biomarker agnostic label in the 3L setting, SVB Leerinks Andrew Berens wrote in a note. Other analysts see a rosier future for the drug, with Wedbush analysts saying we believe meaningful adoption will occur without the genetic test based on the drugs competitive clinical profile. Epizymes stock has declined 16.8 since the start of the year. The SP; 500 is down 3.5.. 